ANN ARBOR, Mich.--(BUSINESS WIRE)--RetroSense Therapeutics LLC announced today that it has been identified and selected by Therapeutic Area Partnerships as a “Top Project to Watch: Most Licensable Products” for the second consecutive year. RetroSense Therapeutics is a privately held biotechnology company at the forefront of developing optogenetic therapies for vision restoration. In October 2014, RetroSense’s lead compound, RST-001 was granted orphan drug designation for retinitis pigmentosa, a genetic disease characterized by deteriorating vision and blindness.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
